Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
30th December 2020 | Thomas Woiwode | 1,347,709 | Open or private purchase | $3.71 | $5,000,000.39 |
14th December 2020 | Thomas Woiwode | 12,783 | Other acquisition or disposition | $0.00 | |
20th October 2020 | Thomas Woiwode | 198,485 | Conversion of derivative | $0.00 | |
20th October 2020 | Thomas Woiwode | 200,000 | Open or private purchase | $15.00 | $3,000,000.00 |
20th October 2020 | Thomas Woiwode | 463,959 | Conversion of derivative | $0.00 | |
20th October 2020 | Thomas Woiwode | 198,839 | Conversion of derivative | $0.00 | |
20th October 2020 | Thomas Woiwode | 2,145,991 | Conversion of derivative | $0.00 | |
20th October 2020 | Thomas Woiwode | 85,065 | Conversion of derivative | $0.00 | |
17th August 2020 | Erin Jones | 10,000 | Exercise of derivative | $0.35 | $3,450.00 |
3rd March 2020 | Thomas Woiwode | 1,049,175 | Conversion of derivative | $0.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Gritstone Oncology, Inc. is a clinical-stage biotechnology company. The company is developing the next generation of cancer immunotherapies to fight multiple cancer types.
23rd December 2020
6th November 2020
6th November 2020
6th November 2020